Society for Neuro-Oncology RSS Feed

16th Quadrennial Meeting of the World Society for Stereotactic & Functional Neurosurgery on 27-May-13 8:30 AM

Mon, 27 May 2013 00:30:00 GMT

16th Quadrennial Meeting of the World Society for Stereotactic & Functional Neurosurgery
Start Date: 27-May-13 8:30 AM
End Time: 30-May-13 5:30 PM
Location: Hotel Nikko Tokyo
Event Details:

The 16th quadrennial meeting of the World Society of Stereotactic and Functional Neurosurgery (WSSFN) will be held in Tokyo, Japan from May 27- 30, 2013.

There is a tremendous amount of novel development in this field particularly with the application of neuromodulation techniques in cutting edge areas including psychiatry, movement disorders, pain and even cognition and dementia. The meeting will highlight world authorities giving plenary lectures, and will feature highly innovative and high-impact presentations selected amongst the very best of the submitted abstracts.

Tokyo is an attractive city and is particularly enjoyable during the month of May. Attendees should take advantage of the local and nearby attractions including the newly built Tokyo Sky Tower and of course Mt Fuji. Do not miss the historical regions like Kyoto, Nara, and Hiroshima which are within 2-3 hours by rapid train.

The conference promises to be an exciting meeting full of discussion, controversy, innovation and friendship.

For registration and complete conference information, visit http://www.wssfn.org/

Hotel Nikko Tokyo

1-9-1 Daiba, Minato-ku

Tokyo, Japan 135-8625

BTEC 2013 Annual Meeting on 4-Jun-13 8:30 AM

Tue, 04 Jun 2013 13:30:00 GMT

BTEC 2013 Annual Meeting
Start Date: 4-Jun-13 8:30 AM
End Time: 7-Jun-13 5:30 PM
Location: Millennium Knickerbocker Hotel, Chicago, IL 60611
Event Details:

Brain Tumor Epidemiology Consortium 2013 Annual Meeting

Getting Back to Basics and Moving into the Future for Brain Tumor Epidemiology

Objectives:

1.To review and brainstorm on ideas for moving brain tumor epidemiology into the future using new technology
2.To explore opportunities for new studies using novel recruitment techniques
3.To review briefly the classifications and biology of low-grade gliomas (LGG) and nonmalignant brain tumors, specifically meningioma, schwannoma, pilocytic astrocytoma, and ganglioglioma.
4.To review the current monitoring and surveillance systems (i.e., registries and databases) for those tumors in children and adults in order to propose new studies using these data
5.To identify and initiate new collaborations on these tumors within BTEC.

For complete program information and registration, click here.

Millennium Knickerbocker Hotel

163 E. Walton Place

Chicago, IL 60611

Montreal International Symposium on Angiogenesis and Metastasis MISAM 2013 on 12-Jun-13 8:30 AM

Wed, 12 Jun 2013 12:30:00 GMT

Montreal International Symposium on Angiogenesis and Metastasis –MISAM 2013
Start Date: 12-Jun-13 8:30 AM
End Time: 14-Jun-13 5:30 PM
Location: McIntyre Medical Sciences Building, Martin Amphitheatre, Montreal, QC
Event Details:

Primary and Metastatic Brain Cancers – Molecular Pathways and Clinical Challenges

The Montreal International Symposium on Angiogenesis and Metastasis, MISAM-2013, will take place in historic and beautiful Montreal on June 12-14, 2013. This bi-annual event aims to bring together scientists working in areas related to disseminated disease, angiogenesis and metastasis in order to tackle together this great challenge common to all cancers, but yet so diverse.

This event has been held twice previously. MISAM 2009 was devoted to metastatic breast cancer and pediatric solid tumours, while MISAM 2011 focused on colorectal cancer. In each case, over 200 scientists met, shared ideas and debated the critical issues of the day. This year (2013), the focus is on disseminated brain tumours, an area where unmet needs could not be greater.

A unique program will be filled with the latest advances, as well as emerging concepts and ideas in key areas of angiogenesis and metastasis research in brain cancer. This will stimulate discussions that will continue outside of the lecture halls and extend beyond the two-day symposium. Montreal, with its picturesque streets, world-renowned restaurants and long-standing tradition of thought, learning, science and humanism will provide the ideal surrounding for this exciting exchange of ideas.

You are invited to MISAM 2013 and to Montreal!

Scientific Committee

Chairs:

Nicole Beauchemin, Ph.D., Goodman Cancer Research Centre, McGill University

Janusz Rak, MD/Ph.D., Montreal Children’s Hospital Research Institute

Nada Jabado, MD/Ph.D., Montreal Children’s Hospital Research Institute

Members:

Pnina Brodt, Ph.D., McGill University Health Centre Research Institute

Josephine Nalbantoglu, Ph.D., Montreal Neurological Institute, McGill University

Peter Siegel, Ph.D., Goodman Cancer Research Centre, McGill University

Speakers:

Steffen Albrecht, MD, MUHC's MontrealChildren's Hospital, McGill University

Barry Bedell, MD/PhD, Montreal Neurological Institute, McGill University

Frederic Charron, PhD, Institut de recherches cliniques de Montréal

Peter Dirks, MD/PhD,The Hospital for Sick Children, University of Toronto

Charles G. Eberhart, MD/PhD, Johns Hopkins University School of Medicine

Paula Foster, PhD, Robarts Research Institute

Frank Furnari, PhD, UC San Diego, Moores Cancer Centre

Eric Holland, MD/PhD, Memorial Sloan-Kettering Cancer Center

Annie Huang, MD/PhD, The Hospital for Sick Children, University of Toronto

Antonio Iavarone, MD, Columbia University Cancer Center

Nada Jabado, MD/PhD, MUHC's MontrealChildren's Hospital Research Institute, McGill University

Mark Kieran, MD/PhD, Dana-Farber Cancer Institute, Harvard Medical School

Thomas Kislinger, PhD, Ontario Cancer Institute, University of Toronto

Mark Lathrop, PhD, Genome Quebec Innovation Centre, McGill University

Josephine Nalbantoglu, PhD, Montreal Neurological Institute, McGill University

James Perry, MD, Sunnybrook Health Sciences Centre, University of Toronto

Kevin Petrecca, MD/PhD, Montreal Neurological Institute, McGill University

Stefan Pfister, MD, German Cancer Research Center,Heidelberg

Heidi Phillips, PhD, Genentech Inc

Janusz Rak, MD/PhD, MUHC's MontrealChildren's Hospital Research Institute, McGill University

David Reardon, MD, Dana-Farber Cancer Institute, Harvard Medical School

Sheila Singh, MD/PhD, McMaster Stem Cell and Cancer Research Institute, McMaster University

Patricia Steeg, PhD, National Cancer Institute, Centre for Cancer Research

Stefano Stifani, PhD, Montreal Neurological Institute, McGill University

Michael Taylor, MD/PhD, The Hospital for Sick Children, University of Toronto

Manuel Valiente-Cortes, PhD, Memorial Sloan-Kettering Cancer Center

Samuel Weiss, PhD, Hotchkiss Brain Institute, University of Calgary

Gelareh Zadeh, MD/PhD, The Hospital for Sick Children, University of Toronto

For further information, visit http://misam.mcgill.ca/

For registration, abstract and poster information, please contact nathalie.magnus@mail.mcgill.ca

McIntyre Medical Sciences Building, Martin Amphitheatre

1200 Pine Ave. W.

Montreal, QC Canada

3rd Annual Brain Metastases Research and Emerging Therapy Conference on 19-Sep-13 8:30 AM

Thu, 19 Sep 2013 14:30:00 GMT

3rd Annual Brain Metastases Research and Emerging Therapy Conference
Start Date: 19-Sep-13 8:30 AM
End Time: 20-Sep-13 5:30 PM
Location: Amphithéâtre Marseille Provence Métropole
Event Details:

The Organizing Committee is pleased to welcome you to Marseille for the third Annual Brain Metastases Research and Emerging Therapy Conference. Last year’s successful edition has prompted us to once again organize this conference. Over the past several months, the EORTC has launched the development of a Brain Metastasis platform, created in August 2012, in order to optimally develop and conduct projects focusing on brain metastases.

This research platform brings together the multidisciplinary approach that is needed to develop brain metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, pathobiology and radiation oncology. It is expected that this cross-sectional platform stimulates innovative and insightful research in a collaborative environment in order to improve the standard of care and methodology of clinical research.

Together, the EORTC, GRPCMac and Canceropole PACA have decided to jointly organize the “Annual Brain Metastases Research and Emerging Therapy Conference” which will be held under the auspices of the EORTC. The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.

For registration, abstract submision, and complete information, visit http://brain-mets.com/

Amphithéâtre Marseille Provence Métropole

Les Jardins du Pharo, 58, Bd Charles Livon

Marseille, France 13007

2nd Minnesota Neuro-Oncology Symposium on 26-Sep-13 7:30 AM

Thu, 26 Sep 2013 12:30:00 GMT

2nd Minnesota Neuro-Oncology Symposium
Start Date: 26-Sep-13 7:30 AM
End Time: 27-Sep-13 5:00 PM
Location: McNamara Alumni Center, Minneapolis, Minnesota
Event Details:

Event Details

This two day event will consist of presentations from experts in neuro-oncology and will be of interest to researchers, physicians, students, patients and families interested in neuro-oncology.

This is an educational event accredited by the Minnesota Medical Association, and this activity has been designated for a maximum of 15.0 AMA PRA Category 1 Credits™.

Session topics include Immunotherapy, Blood Brain Barrier, Genetics and Cell Biology, and Imaging.

Plenary Speakers

Hideho Okada, MD, PhD, University of Pittsburgh, PA
Quentin Smith, PhD, Texas Tech University, Amarillo, TX
David Largaespada, PhD, Director of the Brain Tumor Program, University of Minnesota, Minneapolis, MN
Michael Taylor, MD, PhD, FRCSC, University of Toronto, Toronto, ON
Susan Chang, MD, University of California, San Francisco, CA

Patients and Caregivers

We are including a concurrent program tailored specifically toward patient/caregiver interests that runs the full two days. Patients/caregivers are also encouraged to attend any of the scientific talks as well. Sessions include Brain Tumors 101, Current Therapies, Living with a Brain Tumor, and New Theories and Therapies.

McNamara Alumni Center

200 Oak St. SE

Minneapolis, Minnesota USA

WFNO/SNO Education Day ONLY on 21-Nov-13 8:00 AM

Thu, 21 Nov 2013 16:00:00 GMT

WFNO/SNO Education Day ONLY
Start Date: 21-Nov-13 8:00 AM
End Time: 21-Nov-13 10:00 PM
Location: Marriott Marquis Hotel, San Francisco, CA 94103
Event Details:

This year the Society for Neuro-Oncology is honored to host the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting in San Francisco from November 21st to the 24th. Meeting chairman Dr. Mitchel Berger extends a warm welcome to members of all neuro-oncology societies to share in this unique educational event.

This year's Education Day entitled "From Drug Discovery to Clinic" will address the various aspects of clinical development of agents that range from preclinical testing, pharmacokinetic and pharmacodynamic considerations, first in man studies and the challenges of phase 0-III clinical trials. Concurrent sessions will address the specific challenges of clinical design and specific pathways that are being evaluated in the preclinical arena. Also featured will be a Quality of Life Session with modules focused on Palliative Care, Symptom Management, and Caregiver Challenges.

Marriott Marquis Hotel

55 Fourth Strett

San Francisco, CA USA 94103

WFNO/SNO Scientific Meeting and Education Day on 21-Nov-13 8:00 AM

Thu, 21 Nov 2013 16:00:00 GMT

WFNO/SNO Scientific Meeting and Education Day
Start Date: 21-Nov-13 8:00 AM
End Time: 24-Nov-13 12:00 PM
Location: Marriott Marquis Hotel, San Francisco, California 94103
Event Details:

The Society for Neuro-Oncology is honored to host the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting in San Francisco from November 21st to the 24th. Meeting chairman Dr. Mitchel Berger extends a warm welcome to members of all neuro-oncology societies to share in this unique educational event.

MEETING OVERVIEW

The meeting will build on the traditional SNO format presenting top-scoring abstracts, and invited meet-the-expert sessions.

The Education Day entitled "From Drug Discovery to Clinic" will address the various aspects of clinical development of agents that range from preclinical testing, pharmacokinetic and pharmacodynamic considerations, first in man studies and the challenges of phase 0-III clinical trials. Concurrent sessions will address the specific challenges of clinical design and specific pathways that are being evaluated in the preclinical arena. Also featured will be a Quality of Life Session with modules focused on Palliative Care, Symptom Management, and Caregiver Challenges.

Friday evening, a special “Townhall Meeting” is planned that will review the results of the recent international randomized phase III trials evaluating the use of antiangiogenic strategies for newly diagnosed and recurrent glioblastoma session. This special session will provide a forum for open and interactive discussion about how these results may impact clinical care and efforts for further research.

The social highlight of the meeting will be a gala dinner at the magnificant San Francisco City Hall. Please note that registrants who want to join the gala dinner must buy a ticket to attend. Seats are limited, and it is highly recommended to purchase the ticket during on-line registration as it is likely the gala will be sold-out. To register for the gala (meeting registration required), click here.

Marriott Marquis Hotel

55 Fourth Street

San Francisco, California USA 94103

WFNO/SNO Meeting NOT including Education Day on 22-Nov-13 7:00 AM

Fri, 22 Nov 2013 15:00:00 GMT

WFNO/SNO Meeting NOT including Education Day
Start Date: 22-Nov-13 7:00 AM
End Time: 24-Nov-13 12:00 PM
Location: Marriott Marquis Hotel, San Francisco, CA 94103
Event Details:

MEETING OVERVIEW

The meeting will build on the traditional SNO format presenting top-scoring abstracts, and invited meet-the-expert sessions.

You are invited to join us Thursday evening for a special welcome reception to kick off the meeting. Friday evening, a special “Townhall Meeting” is planned that will review the results of the recent international randomized phase III trials evaluating the use of antiangiogenic strategies for newly diagnosed and recurrent glioblastoma session. This special session will provide a forum for open and interactive discussion about how these results may impact clinical care and efforts for further research.

Marriott Marquis Hotel

55 Fourth Street

San Francisco, CA USA 94103

WFNO/SNO Gala Dinner on 23-Nov-13 7:15 PM

Sun, 24 Nov 2013 03:15:00 GMT

WFNO/SNO Gala Dinner
Start Date: 23-Nov-13 7:15 PM
End Time: 23-Nov-13 10:30 PM
Location: San Francisco City Hall, San Francisco, CA 94102
Event Details:

The beautiful San Francisco City Hall will be the site for our Saturday evening gala. Buses will depart the Marriott Marquis Hotel beginning at 6:50pm and will begin return trips at approximately 9:00pm through 10:30pm.

IMPORTANT: You must have a ticket to board the buses. There will be no onsite ticket sales and no replacements for lost tickets will be available. Seats are limited.

THE VENUE:

San Francisco City Hall, re-opened in 1915, in its open space area in the city's Civic Center, is a Beaux-Arts monument to the City Beautiful movement that epitomized the high-minded American Renaissance of the 1880s to 1917. The structure's dome is the fifth largest in the world. The present building replaced an earlier City Hall that was completely destroyed during the 1906 earthquake

The building as a whole contains some 7,900 tons (7,035 metric tons) of structural steel from the American Bridge Company of Ambridge, Pennsylvania near Pittsburgh. It is faced with Madera County granite on the exterior, and Indiana sandstone within, together with finish marbles from Alabama, Colorado, Vermont, and Italy. Much of the statuary is by Henri Crenier.

The Rotunda is a spectacular space and the upper levels are public and handicapped accessible. Opposite the grand staircase, on the second floor, is the office of the Mayor. Bronze busts of former Mayor George Moscone and his successor, Dianne Feinstein, stand nearby as tacit reminders of the Moscone assassination, which took place just a few yards from that spot in the smaller rotunda of the mayor's office entrance. A bust of former county supervisor Harvey Milk, who was assassinated in the building was unveiled on May 22, 2008.

We look forward to this special event and the opportunity to showcase a unique part of San Francisco's past.

San Francisco City Hall

1 Drive Carlton B. Goodlett Place

San Francisco, CA USA 94102

Audio/Slide Content from the 2012 SNO Meeting Now Available at no Charge

Linda Greer - noemail@soc-neuro-onc.org — Wed, 06 Feb 2013 13:00:00 GMT

SNO is pleased to offer content from the 2012 Annual Meeting in Washington DC as part of an expanded benefit initiative. Selected slide presentations have been synched with their accompanying audio and are now available at no charge to all who wish to view them.

Please note that this content is intended as an educational resource for conference attendees only. Reproduction, distribution or dissemination of the content by any means is strictly prohibited.

To access this content:

1. Go to www.starlibraries.com/sno

2. Choose "Browse Sessions" in the upper left area of the site. There is no need to create an account or enter any login information.

3. Select sessions and individual presentations as desired.

4. Please note that this represents the majority, although not the entirety, of presentations given during the meeting.

For technical assistance with StarLibraries, please contact AVMG staff at support@starlibraries.com or by phone at 800-283-2864.

For all other SNO related inquiries, please contact Linda Greer, linda@soc-neuro-onc.org

6-Feb-13 7:00 AM

Abhijit Guha Fund for International Neuro-Oncology Outreach

Linda Greer - noemail@soc-neuro-onc.org — Fri, 25 Jan 2013 16:00:00 GMT

SNO Launches International Neuro-Oncology Outreach Effort

The Abhijit Guha Fund for International Neuro-Oncology Outreach is an initiative of the SNO Foundation designed to promote clinical and research activities in both pediatric and adult neuro-oncology in developing regions of the world.

Click here to make a pledge today!

The Need

Brain tumors know no boundaries and in developing regions of the world, the need for trained neuro-oncology professionals is especially acute. In order for the SNO Foundation to reach out to these unserved areas, we need your support. SNO members and friends of our Society are asked to review the attached pledge form and consider making a contribution to help fund our international efforts. And, to extend your gift further, please note that all donations to the fund will be matched, dollar for dollar, by the SNO Foundation!

About Abhijit Guha
Abhijit (Ab) Guha was the sixth president of the Society for Neuro-Oncology. Dr. Guha was an accomplished neurosurgeon who maintained an active research laboratory, and trained numerous post-doctoral fellows, residents, and students in neurooncology research. Throughout his career, he was devoted to advancing neuro-oncology education in underserved areas. Correspondingly, the Abhijit Guha International Outreach Fund seeks to recognize Dr. Guha’s global contributions to the field and create a lasting legacy that will continue this work in his name.

How You Can Help
SNO members are encouraged to help our outreach efforts by joining the SNO International Outreach Committee. But we also need your financial support – please consider making a pledge today!

25-Jan-13 10:00 AM

SNO mourns the loss of John Ohlfest, PhD

Linda Greer - noemail@soc-neuro-onc.org — Fri, 25 Jan 2013 16:00:00 GMT

The Society for Neuro-Oncology is saddened to report the untimely death of one of its members, John Ohlfest Ph.D., from melanoma. John was a promising young investigator who, in his short career, had already made multiple contributions to the field of neuro-oncology. Known for his endless ambition and creative thinking, John designed new treatments for human and canine brain cancers, some of which are currently undergoing clinical trial. Having finished his graduate studies in only 3 years, John joined the faculty of the University of Minnesota in 2005 in the departments of Neurosurgery and Pediatrics, and in 2010, he was awarded a McKnight Land-Grant Professorship. In 2012, he was named as the inaugural holder of the Hedberg Family/Children's Cancer Research Fund Chair in Brain Tumor Research.

John is survived by his wife, Karen, daughter, Grace, and son, Lucas. His passion, influence and contributions to brain cancer research were inspirational to his many colleagues and friends. The Ohlfest Memorial Education Fund has been established to provide for the education of John’s children. Donations can be made to this fund at any Wells Fargo location or by mailing a donation to: Ohlfest Memorial Education Fund, PO Box 131477, Roseville, MN 55113.

25-Jan-13 10:00 AM

Neuro-Oncology’s New Impact Factor is 5.723

Chas Haynes - noemail@soc-neuro-onc.org — Sun, 09 Sep 2012 15:00:00 GMT

The Society for Neuro-Oncology and the editorial office of Neuro-Oncology are pleased to announce that Thomson’s ISI Web of Knowledge Journal Citation Report has assigned Neuro-Oncology an ISI Impact Factor of 5.723 in its most recent ranking. Solidifying the journal’s reputation as the leading journal in its field, this rating places Neuro-Oncology ahead of its direct peer neuro-oncology journals, establishing it as fifteenth among all ranked clinical neurology journals and twenty-second among other oncology journals.

WK Alfred Yung, the journal's editor in chief commented: "I am delighted that Neuro-Oncology has achieved such a high impact factor this year, further cementing its position as the leading journal in the field. I’d like to thank our highly dedicated editorial team, authors and reviewers for their contributions and ongoing support, which enables us to provide the highest quality research to our readers.”

9-Sep-12 10:00 AM

2012 Neuro-Tumor Club Recap

Chas Haynes - noemail@soc-neuro-onc.org — Mon, 23 Jan 2012 19:00:00 GMT

18th Neuro-Tumor Club Dinner Meeting at AACR

Event Date: Monday April 2, 2012; 6:30–10:00pm
Location: Hotel Allegro, 171 W. Randolph, Chicago, IL

Meeting Chair: Jeffery Raizer, MD

The 18th Annual Neuro-Tumor Club Dinner Meeting took place on April 2, 2012, at the Allegro Hotel in Chicago, Illinois. This meeting, for brain tumor researchers attending the AACR Annual Meeting, was organized by the Society for Neuro-Oncology with the support of Castle Biosciences, Inc., Genentech, Merck and the National Brain Tumor Society.

The event drew approximately 150 investigators from diverse disciplines relevant to brain tumor research, and was very successful in strengthening existing personal research connections and collaborations, generating new associations and presenting the group with updates in topics important to brain tumor research.

Twenty-eight abstracts were received of uniformly high quality, a slight increase from the 2011 event. Submissions came from seven countries and were reflective of the cutting edge, thought-provoking basic and translational research in the field of neuro-oncology. Trying to reduce this to fourteen talks was difficult given the standard of the submissions; however the meeting chair, Jeffrey Raizer, MD, did an excellent job of selecting talks that well represented a broad range of important topics and themes.

The talks were in four consecutive sessions that encompassed the following topic areas:

New Gene and Immunotherapy
Geno/Phenotyping and PersonalizedTherapy/Stem Cells/Tumor Biology
Angiogenesis and Tumor Microenvironment
New Tools and Translational Science

Each topic area was excellently framed by over-views from authority figures in those areas including Derek Wainwright (New Gene and Immunotherapy); Alexander Stegh (Geno/Phenotyping and PersonalizedTherapy/Stem Cells/Tumor Biology); Ian Miller (Angiogenesis and Tumor Microenvironment) and Adilia Hormigo (New Tools and Translational Science).

The dinner took place at the Allegro Hotel, a boutique property near the 2012 Annual AACR Meeting. Attendees’ registration continued right up to the dinner and in the end there were over one hundred and fifty researchers present. The fourteen speakers were scheduled over three hours, requiring a tight time-line, which was kept judiciously by all presenters. All speakers managed to finish on time and yet conveying an astonishing amount of background information and experimental data. The talks were followed by lively discussions.

There were many excellent presentations during the night. In the first session, Derek Wainwright presented data on IDO, which might have implications for a new therapeutic target. In the next session, Anat Erdreich-Epstein presented a novel new gene that affected tumorogeneis. More research into this might again lead to novel therapies. In session three, Chad Potts showed interesting findings in medulloblastoma signaling that was paralleled in normal brain development in the Sonic hedgehog and HIF-1 alpha pathway. The final session had four excellent presentations that showed data on how targeting certain abnormalities would lead to better tumor control; these included targets of lipid metabolism, microglia, notch inhibition and the use of oncolytic adenovirus. The evening concluded with many of the attendees remaining to engage in informal conversation prompted by the presented topics.

Members are encouraged to mark their calendars for the next Neuro-Tumor Club Dinner, scheduled to take place on Monday, April 8th, 2013, in Washington, DC.

SNO would like to thank Jeffery Raizer, MD, for chairing the 2012 Neuro-Tumor Club Dinner.

Questions? Contact: Linda Greer

23-Jan-12 1:00 PM

New Public Data Resource from the NIH Common Fund’s Epigenomics Program

Fri, 29 Jul 2011 12:00:00 GMT

Researchers in the Reference Epigenome Mapping Consortium, part of the NIH Common Fund’s Roadmap Epigenomics Program (http://commonfund.nih.gov/epigenomics), have begun creating a community resource of genome-wide epigenetic maps in a variety of human primary cell and tissue types. The data currently represent more than 100 samples including adult and fetal cells and tissues, and embryonic and induced pluripotent stem cells. The majority of reference epigenomes being generated contain information about DNA methylation, a core set of histone modifications, chromatin accessibility, and gene expression. A subset of reference epigenomes will also contain an expanded set of at least twenty additional histone modifications. The Consortium’s website (http://roadmapepigenomics.org) provides information about protocols developed by Consortium members, information about data standards, and links to a variety of sites where the epigenomic data can be visualized in a genome browser or downloaded for subsequent analysis

29-Jul-11 7:00 AM

2009-2010 Central Brain Tumor Registry of the US Statistical Report

Jan Esenwein - noemail@soc-neuro-onc.org — Sat, 20 Mar 2010 15:00:00 GMT

The Central Brain Tumor Registry of the United States (CBTRUS) announces the publication of its latest statistical report, 2009-2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006 (available online at www.cbtrus.org). Data collected by the National Program of Cancer Registries (CDC) and SEER (NCI) from 47 population-based cancer registries were analyzed resulting in an incidence rate of 18.71 cases per 100,000 person-years for all primary brain & central nervous system (CNS) tumors. CBTRUS estimates that 62,930 new cases of primary non-malignant and malignant brain and CNS tumors are expected to be diagnosed in the United States in 2010. Meningioma had the highest incidence and accounted for 33.8% of all primary brain tumors in 2004-2006. Gliomas, including glioblastoma, accounted for 32% of these tumors and 80% of all malignant brain tumors.

This Statistical Report continues the past efforts CBTRUS has made to provide accurate, population–based incidence rates for all primary brain and CNS tumors by histology, age, gender, race and Hispanic origin. As in previous reports, these data have been listed in histologic groupings with improved clinical relevance

Funding for the Central Brain Tumor Registry of the United States in 2008-2009 has been provided by the American Brain Tumor Association (www.abta.org) , the National Brain Tumor Society (www.braintumor.org) , the Pediatric Brain Tumor Foundation (www.pbtfus.org) and from the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract # HHSN26100800766P.

Printed booklets may be requested by contacting cbtrus@aol.com.

20-Mar-10 10:00 AM

2009 Joint Meeting of SNO and AANS/CNS Section on Tumors

noemail@soc-neuro-onc.org — Mon, 03 Aug 2009 18:00:00 GMT

The Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors are joining scientific research efforts to present the latest developments in neuro-oncology and tumor surgery at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, October 22-24, 2009 in New Orleans, Louisiana. Register now for the most comprehensive review of cutting-edge laboratory and clinical research in the field of neuro-oncology and tumors! Register for the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors today! The CNS is also offering special registration rates for Joint Meeting attendees who also register for the CNS Annual Meeting. Register through September 23, 2009 and you will receive up to 25% in savings on both meetings. In addition to this exclusive registration rate, the CNS is also offering a number of courses that members of the SNO and the AANS/CNS Section on Tumor attendees will find of value -...

4th Quadrennial Meeting of the World Federation of Neuro-Oncology

Thu, 23 May 2013 11:20:20 GMT

4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology November 21-24, 2013 San Francisco, California Marriott Marquis Hotel Scientific Chair: Mitchel Berger, MD This year the Society for Neuro-Oncology is honored to host the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting in San Francisco from November 21st to the 24th. Meeting chairman Dr. Mitchel Berger extends a warm welcome to members of all neuro-oncology societies to share in this unique educational event. Abstract Deadline has now Passed (For detailed abstract submission guidelines, click here.) For important information on the new Late-Breaking abstract category, click here) MEETING OVERVIEW The meeting will build on the traditional SNO format presenting top-scoring abstracts, and invited meet-the-expert sessions. The Education Day entitled From Drug...

*****home:spotlight

Sun, 19 May 2013 21:04:46 GMT

2nd Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference

The second Pediatric Neuro-Oncology Basic and Translational Research Conference was held May 16 - 17, 2013 at the Hyatt Pier 66 Hotel in Fort Lauderdale, FL. Building on the success of our 2011 event, this year's conference attracted over 270 attendees from 15 countries, with research drawn from more than 180 accepted abstracts. Chair, Dr. James Rutka, and the Scientific Program Committee organized an outstanding program, featuring the most up-to-date pediatric basic and translational research. A full recap will be posted in the coming weeks.

2013 WFNO/SNO Meeting Registration Options and Gala Dinner Tickets

Thu, 02 May 2013 13:56:30 GMT

Please review the following registration information before proceeding: REGISTRATION CATGORIES: Member - registrant must be a current 2013 or 2014 member of one of the national or international neuro-oncology societies, such as SNO, EANO, JSNO, etc. By registering at the member rate, the registrant certifies that he/she meets this requirement. Trainee - registrant must be a student or actively involved in training (residency, fellowship, etc.). May not hold a faculty appointment Allied Health- registration for nursing professionals, social workers, physical therapists, psychologists, etc. Spouse/Guest- limited to social events and meals only (excluding Saturday evening gala dinner) and does not provide acces to scientific sessions. Must accompany a paid registrant. Non-member- all other health professionals OTHER INFORMATION Gala Dinner: Separate registration and payment required for the Saturday evening gala dinner. Limited...

WFNO/SNO 2013 Hotel Information

Tue, 30 Apr 2013 16:17:13 GMT

MARRIOTT MARQUIS HOTEL

The 39-story San Francisco Marriott Marquis has been chosen as the conference hotel for this year's meeting. Situated at the intersection of Fourth and Mission Streets, across from the Sony Metreon and Moscone Convention Center, the building is recognizable by the distinctive postmodern appearance of its high-rise tower. It holds the distinction as the second tallest hotel in San Francisco.

To book a room online*, click here.

*Hotel has very limited availability for Tuesday, November 19.

For phone inquiries or to make changes to existing reservations, call 1-877-622-3056 or if outside the US, 415-896-1600 (when calling this number, ask for Passkey Reservations). Do not call the hotel directly for information on new or existing reservations. If you have general questions regarding the conference hotel, contact Linda Greer linda@soc-neuro-onc.org.

International Outreach

Mon, 29 Apr 2013 14:50:12 GMT

Annual Meeting Travel Scholarships Travel scholarships are awarded each year for international attendees from eight different geographical regions (one per region): Central America & the Caribbean, Central and Southern Africa, China & Associated Countries, Eastern Europe, Far East and Australasia, Indian Sub-Continent, North Africa & the Middle East and South America. The deadline for scholarships to the 2013 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, being held in conjunction with the 18th annual Scientific Meeting and Education Day of the Society for Neuro-Oncology is July 1, 2013. To download the application, click here. Recap of the Brain Tumor Worshop Held in Morocco Organized by representatives of the Moroccan Society of Hematology and Pediatric Oncology, St. Jude Children's Research Hospital and the International Outreach Committee of the Society of Neuro-Oncology, a Brain Tumor Workshop was held in...

**Event Template -left column - Quick Links

Wed, 24 Apr 2013 11:22:11 GMT

Quick Links

2013 Neuro Tumor Club Dinner at AACR

Fri, 22 Mar 2013 11:28:25 GMT

Washington Plaza Hotel, 10 Thomas Circle, NW Washington, DC Monday April 8, 2013, 6:30-10:00pm No Charge to Attend - RSVP Required Download Form or RSVP to linda@soc-neuro-onc.org Deadline to register your attendance Monday, April 1 Program 6:30-7:00 Buffet Dinner Service 7:00-7:05 Welcome & Introduction: Co-Chairs John Park and Raymund Yong, National Institutes of Health Session 1 Animal Models, Biomarkers and Stem Cells 7:05-7:10 Overview: Justin Lathia, Cleveland Clinic Foundation, Cleveland, OH 7:10-7:20 Genetic Mosaic Mouse Models for Brain Tumors: Basic Research and Pre-Clinical Applications Hui Zong, University of Virginia, Charlottesville, VA 7:20-7:30 sncRNA Signature Found in Microvesicles of GBM Patient Serum Serves as a Diagnostic Marker Marta Alonso, University Hospital of Navarra, Spain 7:30-7:40 A Human...

Abstract Submission Guidelines

Wed, 13 Mar 2013 19:28:27 GMT

Eligibility You do not need to be a SNO member to submit an abstract, and there is no limit on the number of abstracts you may submit. Submitted abstracts must not have been previously published. Deadlines The deadline for abstract submission is May 22, 2013. If you withdraw your abstract after August 1, the publisher may not have time to delete the abstract from the publication file. Format The body of the abstract (not including title, authors and author affiliations) must not exceed 300 words Tables and figures are not allowed How to use the online abstract submission system Note: If you are submitting more than one abstract, you can use the same login for each abstract. You can alter your abstracts at any time up to the deadline Do not include author names in the title or body of your abstract 1. The submission process Log in to the submission system when you have prepared your abstract: enter your email...

2013 Media Guidelines, Press Coverage, and Embargo Information

Thu, 07 Mar 2013 15:10:32 GMT

The Society for Neuro-Oncology is pleased to offer complimentary registration to professional journalists representing media organizations for the express purpose of gathering news and information to produce media coverage of the meeting.

The SNO annual meeting is open to representatives of print, broadcast and web-based media and health care trade media (collectively known as press), as well as public information officers from educational institutions, government agencies and nonprofit cancer research organizations.

For the complete media policy, guidelines and restrictions, click here.

To apply for press credentials to the 2013 4th Quadrennial World Federation of Neuro-Oncology Meeting, in conjunction with the the 18th Annual Society for Neuro-Oncology Scientific Meeting and Education day, click here.

Return application with required documentation to linda@soc-neuro-onc.org or fax to 713-583-1345.

Submission deadline: October 20, 2013

2013 Late Breaking Abstracts

Wed, 06 Mar 2013 20:13:15 GMT

New this year, the Society for Neuro-Oncology will allow authors to submit their Late-Breaking research for consideration for the 2013 scientific meeting program. SNO recognizes that some rapidly advancing investigations may include results that will not be available at the time of the abstract submission deadline of May 22nd, 2013.

Please note that only a limited number of abstracts (not to exceed six) from this Late-Breaking category will be selected for oral presentation at the meeting in San Francisco.

Authors should note the following important information before submitting a Late-Breaking Abstract:

Late-Breaking abstracts will be considered for oral presentation only.
Late-Breaking abstracts accepted for oral presentation will not be included in the printed abstract supplement to Neuro-Oncology, and will be published electronically.
Late-Breaking abstracts not accepted for presentation will not be considered for any type of presentation format (poster, poster discussion or oral) and will not be part of the annual meeting program.
Late-Breaking abstracts will not be considered for awards.

This category is not intended to offer a second deadline for regular abstract submissions.

In order for an abstract to be considered for Late-Breaking Abstract status, the submitting author must:

Select the “Late-Breaking Abstract” check box in the abstract submission program.
Submit an abstract, including the objectives and methods but excluding the results and conclusions of the research, by the regular submission deadline of May 22, 2013.
Include the date of planned analysis in the abstract.
Submit a final Late-Breaking abstract (with updated data) by September 1, 2013. If an updated abstract is not submitted by that date, the abstract will be automatically rejected.

Authors will be notified within two weeks of the September 1st deadline if their abstract has been accepted for presentation.

Lorem ipsum survey

noemail@soc-neuro-onc.org — Fri, 20 Mar 2009 16:43:12 GMT

Objectives:

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummynibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat. Ut wisis enim ad minim veniam, quis nostrud exerci tution ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis te feugifacilisi.

Duis autem dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit au gue duis dolore te feugat nulla facilisi.

Ut wisi enim ad minim veniam, quis nostrud exerci taion ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.